Radiation therapy is one approach to treating early-stage (localized) prostate cancer, but in some men the prostate cancer returns. The purpose of this study is to determine if giving an investigational therapy called ProstAtak to men receiving radiation therapy for localized prostate cancer reduces the risk of recurrence.
ProstAtak consists of a “vector” which carries a piece of a gene from the herpes virus into prostate tumor cells. The vector is injected into the tumor. The patient then receives a herpes drug called valacyclovir, which is changed inside the tumor by the herpes virus gene into a chemical that can kill tumor cells.
Patients in this study will be randomly assigned to receive ProstAtak or a placebo solution via injection, in addition to standard radiation therapy and valacyclovir. Researchers will monitor both groups of patients for several years to life to compare their outcomes.